|Dear Seed Investor,
NetworkNewsWire today released an article looking at the economic impact that InMed's proprietary biosynthesis could have on the cannabis industry, while looking at the process of other large industry players.
The article looks at the current industry process of extraction, the challenges it faces, and how InMed's process could affect it.
"InMed’s innovative process targets significant cost savings as well as enhanced production, purification and quality control compared to existing grow-harvest-extract-purify methods employed by other companies."
Here's an excerpt below, but we recommend reading the full article.
NetworkNewsWire Editorial Coverage: According to a recent Haywood Securities research report, the value of the cannabidiol (CBD) market is expected to hit $2.1 billion by 2020.
CBD is just one compound out of more than 90 found within the cannabis plant, though.
While many companies with an interest in medicinal marijuana pursue various avenues to extract cannabinoids, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting, eliminating most of the costly requirements that typically come with cannabinoid extraction.
To understand the value of this process, it helps to take a look at the methods utilized by other industry players such as GW Pharmaceuticals (NASDAQ: GWPH) and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), as well as the challenges of high-volume cannabis cultivators like Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF) and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF).
Fueled by mounting increases in consumer demand and expanding legalization, the race is on to find a cost effective method of extracting medicinal-grade cannabinoids.
To glean pharmaceutically-viable cannabinoid compounds, cannabis must first be physically grown in quantity.
Then, the cannabinoids are extracted and processed in an attempt to meet the exacting purity levels required by regulatory standards.
Sourcing cannabinoids naturally requires planting, growing, harvesting, extracting and purifying huge quantities of plants.
Breath of Life Pharma, recently featured in a Rolling Stone article, had to dedicate one million square feet of cannabis cultivation space in order to produce enough raw flower for its extraction business.
Producing compounds from plant extracts is time consuming and expensive, and, despite cultivating thousands of tons of cannabis, most companies in this arena can only produce a couple of the 90+ cannabinoids present in the plant. Many cannabinoids are found only in trace amounts and will never be accessible or economically feasible with current extraction methods.
Click to read full article
The Seed Investor